Flora Growth Corp. (NASDAQ: FLGC) recently announced the next stage of its development with the creation of Flora Pharma and the execution of an agreement to begin scientific clinical trials globally. Flora Pharma’s formation follows the acknowledgment and commitment by the management team and board of directors to move ahead with applied research initiatives in medical cannabis in order to become a leader in the discovery, development, manufacturing and commercialization of novel, phytocannabinoid-based prescription medicines and nutraceutical products to address a broad range of diseases. The company also signed an agreement to begin scientific clinical trials on the use of cannabinoids to treat fibromyalgia and chronic pain, with the primary research sites for the global effort located in the U.S. and U.K. “Our team is incredibly excited to announce our entry into cannabinoid science,” president and CEO Luis Merchan was quoted in a recent article. “Commercial harvests are well underway, and it is now that we’re able to turn our attention to what we believe is the long-term future of our industry and to hedge ourselves further against the commoditization of raw cannabis materials.”
To view the full article, visit https://cnw.fm/XHPdb
About Flora Growth Corp.
Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC
About HempWire
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/Disclaimer
Do you have questions or are you interested in working with HW? Ask our Editor
HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
HempWire is part of the InvestorBrandNetwork.
